DEPO-TESTOSTERONE INJ 100MG/ML 100 MG
TESTOSTERONE CYPIONATE : 100 MG · DIN 00030783 · PFIZER CANADA ULC
Health Canada status: CANCELLED POST MARKET
What is DEPO-TESTOSTERONE INJ 100MG/ML?
DEPO-TESTOSTERONE INJ 100MG/ML 100 MG contains TESTOSTERONE CYPIONATE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 00030783, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 18-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DEPO-TESTOSTERONE INJ 100MG/ML used for?
DEPO-TESTOSTERONE (testosterone cypionate injection) is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). DEPO-TESTOSTERONE should not be used to treat non-specific symptoms suggestive of hypogonadism if testosterone deficiency has not been demonstrated and if other etiologies responsible for the symptoms have not been excluded.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00030783 |
|---|---|
| Brand name | DEPO-TESTOSTERONE INJ 100MG/ML |
| Generic / active ingredient | TESTOSTERONE CYPIONATE : 100 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 100 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | CONTROLLED DRUGS (CDSA IV) |
| ATC code | G03BA03 TESTOSTERONE |
| AHFS class | 68:08.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 18-Jul-2025 |
| Original market date | 1953-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is TESTOSTERONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code G03BA03 TESTOSTERONE. 10 of 27 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ANDROGEL | 1 % | GEL | BGP PHARMA ULC | MARKETED | DIN 02245346 |
| ANDROGEL | 1 % | GEL | BGP PHARMA ULC | MARKETED | DIN 02245345 |
| ANDROGEL | 12.5 MG | GEL | BGP PHARMA ULC | MARKETED | DIN 02249499 |
| NATESTO | 4.5 % | GEL | ACERUS BIOPHARMA INC | MARKETED | DIN 02450550 |
| TARO-TESTOSTERONE | 40 MG | CAPSULE | TARO PHARMACEUTICALS INC | MARKETED | DIN 02421186 |
| TARO-TESTOSTERONE CYPIONATE INJECTION | 100 MG | SOLUTION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02496003 |
| TARO-TESTOSTERONE GEL | 1 % | GEL | TARO PHARMACEUTICALS INC | MARKETED | DIN 02463806 |
| TARO-TESTOSTERONE GEL | 1 % | GEL | TARO PHARMACEUTICALS INC | MARKETED | DIN 02463792 |
| TESTIM 1% | 1 % | GEL | ENDO OPERATIONS LTD. | MARKETED | DIN 02280248 |
| TESTOSTERONE ENANTHATE INJECTION, USP | 200 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02536315 |
Who else supplies TESTOSTERONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TESTOSTERONE appears in 92 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.